Skip to content
RetRetRet160160160556255625562

Drawing based on the label description. No photo yet.

“160 mg: light pink, film coated, round tablet debossed with "Ret 160" on one side and "5562" on the other side”

Ret160 5562 pill

Pill with imprint Ret160 5562 is pink, round, 10 mm and has been identified as Selpercatinib 160 mg. It is used for lung cancer and thyroid neoplasms. It is supplied by Eli Lilly and Company.

Selpercatinib 160 mg

Imprint
Ret160 5562
Strength
160 mg
Used for
Lung cancer and thyroid neoplasms
Color
Pink
Shape
Round
Size
10 mm
Score
No score line
Form
Tablet, coated
Manufacturer
Eli Lilly and Company
Drug class
Cancer medicine (kinase inhibitor)
NDC
0002-5562, 0002-5562-60

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Selpercatinib pills and guides

What is Selpercatinib used for?

Selpercatinib is used for lung cancer and thyroid neoplasms.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

RET Fusion-Positive Non-Small Cell Lung Cancer

RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.

RET-Mutant Medullary Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.

RET Fusion-Positive Thyroid Cancer

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Other RET Fusion-Positive Solid Tumors

RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

From the FDA-approved label on DailyMed (published Sep 14, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows Ret 160 and the other side shows 5562.
  • It is pink, round, 10 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Retevmo.

Ingredients

Active: Selpercatinib

Inactive: Microcrystalline Cellulose, Croscarmellose Sodium, Hydroxypropyl Cellulose, Unspecified, Water, Mannitol, Sodium Stearyl Fumarate, Polyvinyl Alcohol, Unspecified, Titanium Dioxide, Polyethylene Glycol, Unspecified, Talc, Ferric Oxide Red

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Selpercatinib pills